PDCD1 and neoplasm: However, a recent open-label pilot study showed that treatment with anti-PD-1 (programmed cell death protein 1) antibody (pembrolizumab) prior to tumor resection escalated both local and systemic antitumor immune responses in recurrent GBMs, and patients had significantly extended overall survival [114].